| Company | Date | Position | Consensus β | Price Target β | 1-Yr Return | vs S&P 500 β |
|---|---|---|---|---|---|---|
|
GILD
Gilead Sciences
|
Oct 30, 2026 | BUY |
Strong Buy
-27.3% avg upside
66 analysts
|
$200.00
17.22% Upside
|
+2.2% | Β· |
|
CAMP
CAMP4 Therapeutics Corporation
|
Oct 15, 2026 | BUY |
Strong Buy
+144.9% avg upside
11 analysts
|
$8.00
102.08% Upside
|
+13.5% | Β· |
|
PCVX
Vaxcyte
|
Oct 05, 2026 | BUY |
Strong Buy
+77.8% avg upside
15 analysts
|
$122.00
96.75% Upside
|
-13.5% | Β· |
|
STTK
Shattuck Labs
|
Oct 02, 2026 | BUY |
Strong Buy
+276.2% avg upside
16 analysts
|
$19.00
241.80% Upside
|
-31.4% | Β· |
|
VIR
Vir Biotechnology
|
Sep 28, 2026 | BUY |
Strong Buy
+127.8% avg upside
16 analysts
|
$18.00
59.38% Upside
|
+16.2% | Β· |
|
IONS
Ionis Pharmaceuticals
|
Sep 23, 2026 | BUY |
Strong Buy
+74.1% avg upside
44 analysts
|
$86.00
97.67% Upside
|
-35.4% | Β· |
|
ALNY
Alnylam Pharma
|
Sep 17, 2026 | BUY |
Strong Buy
+76.3% avg upside
53 analysts
|
$357.00
116.31% Upside
|
-36.5% | Β· |
|
BIOA
BioAge Labs, Inc.
|
Sep 14, 2026 | BUY |
Strong Buy
+506.9% avg upside
9 analysts
|
$35.00
496.29% Upside
|
-34.7% | Β· |
|
IFRX
InflaRx
|
Sep 14, 2026 | BUY |
Strong Buy
+430.1% avg upside
12 analysts
|
$8.00
381.83% Upside
|
-16.8% | Β· |
|
MRNA
Moderna
|
Aug 19, 2026 | HOLD |
Hold
-48.5% avg upside
38 analysts
|
β | +56.0% | Β· |
|
PLRX
Pliant Therapeutics
|
Aug 12, 2026 | HOLD |
Buy
+2494.6% avg upside
21 analysts
|
β | -24.3% | Β· |
|
ANNX
Annexon Biosciences
|
Aug 12, 2026 | BUY |
Strong Buy
+274.9% avg upside
14 analysts
|
$25.00
517.29% Upside
|
-21.2% | Β· |
|
RYTM
Rhythm Pharmaceuticals
|
Aug 04, 2026 | BUY |
Strong Buy
+39.2% avg upside
23 analysts
|
$130.00
40.46% Upside
|
-0.7% | Β· |
|
VRTX
Vertex Pharmaceuticals
|
Aug 04, 2026 | HOLD |
Strong Buy
-20.5% avg upside
62 analysts
|
β | +13.3% | Β· |
|
STOK
Stoke Therapeutics
|
Aug 04, 2026 | BUY |
Strong Buy
+55.8% avg upside
18 analysts
|
$40.00
52.11% Upside
|
-16.2% | Β· |
|
PHAT
Phathom Pharmaceuticals
|
Jul 30, 2026 | BUY |
Strong Buy
+316.6% avg upside
15 analysts
|
$22.00
283.28% Upside
|
-41.9% | Β· |
|
LXRX
Lexicon Pharmaceuticals
|
Apr 21, 2025 | HOLD |
Buy
+216.5% avg upside
10 analysts
|
β | +221.1% | Β· |
|
TVRD
Tvardi Therapeutics
|
Aug 16, 2024 | HOLD |
Strong Buy
+2090.0% avg upside
24 analysts
|
β | +99.0% | Β· |
|
ACAD
ACADIA Pharmaceuticals
|
Aug 05, 2021 | BUY |
Strong Buy
+71.5% avg upside
43 analysts
|
$26.00
26.33% Upside
|
-14.6% | Β· |
|
NBIX
Neurocrine
|
Aug 04, 2021 | HOLD |
Strong Buy
+27.3% avg upside
37 analysts
|
β | +2.9% | Β· |
|
CRSP
Crispr Therapeutics AG
|
Apr 28, 2021 | BUY |
Buy
+45.6% avg upside
41 analysts
|
$170.00
230.56% Upside
|
-61.9% | Β· |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.